Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States.
Altruism
Empirical ethics
End-of-life
HIV cure research
Last Gift
People with HIV
Rapid research autopsy
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
11 01 2022
11 01 2022
Historique:
received:
06
01
2021
accepted:
21
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
29
4
2022
Statut:
epublish
Résumé
One of the next frontiers in HIV research is focused on finding a cure. A new priority includes people with HIV (PWH) with non-AIDS terminal illnesses who are willing to donate their bodies at the end-of-life (EOL) to advance the search towards an HIV cure. We endeavored to understand perceptions of this research and to identify ethical and practical considerations relevant to implementing it. We conducted 20 in-depth interviews and 3 virtual focus groups among four types of key stakeholders in the United States (PWH, biomedical HIV cure researchers, HIV clinicians, and bioethicists) to obtain triangulated viewpoints because little was known about the ethics of this topic. Each group was queried as to ethical considerations, safeguards, and protections for conducting HIV cure-related research at the EOL to ensure this research remains acceptable. All four key stakeholder groups generally supported HIV cure-related research conducted at the EOL because of the history of altruism within the PWH community and the potential for substantial scientific knowledge to be gained. Our informants expressed that: (1) Strong stakeholder and community involvement are integral to the ethical and effective implementation, as well as the social acceptability of this research; (2) PWH approaching the EOL should not inherently be considered a vulnerable class and their autonomy must be respected when choosing to participate in HIV cure-related research at the EOL; (3) Greater diversity among study participants, as well as multi-disciplinary research teams, is necessitated by HIV cure-related research at the EOL; (4) The sensitive nature of this research warrants robust oversight to ensure a favorable risk/benefit balance and to minimize the possibility of therapeutic misconception or undue influence; and (5) Research protocols should remain flexible to accommodate participants' comfort and needs at the EOL. Because of the ethical issues presented by HIV cure-related research at the EOL, robust ethical safeguards are of utmost importance. The proposed ethical and practical considerations presented herein is a first step in determining the best way to maximize this research's impact and social value. More much inquiry will need to be directed towards understanding context-specific and cultural considerations for implementing EOL HIV cure research in diverse settings.
Sections du résumé
BACKGROUND
One of the next frontiers in HIV research is focused on finding a cure. A new priority includes people with HIV (PWH) with non-AIDS terminal illnesses who are willing to donate their bodies at the end-of-life (EOL) to advance the search towards an HIV cure. We endeavored to understand perceptions of this research and to identify ethical and practical considerations relevant to implementing it.
METHODS
We conducted 20 in-depth interviews and 3 virtual focus groups among four types of key stakeholders in the United States (PWH, biomedical HIV cure researchers, HIV clinicians, and bioethicists) to obtain triangulated viewpoints because little was known about the ethics of this topic. Each group was queried as to ethical considerations, safeguards, and protections for conducting HIV cure-related research at the EOL to ensure this research remains acceptable.
RESULTS
All four key stakeholder groups generally supported HIV cure-related research conducted at the EOL because of the history of altruism within the PWH community and the potential for substantial scientific knowledge to be gained. Our informants expressed that: (1) Strong stakeholder and community involvement are integral to the ethical and effective implementation, as well as the social acceptability of this research; (2) PWH approaching the EOL should not inherently be considered a vulnerable class and their autonomy must be respected when choosing to participate in HIV cure-related research at the EOL; (3) Greater diversity among study participants, as well as multi-disciplinary research teams, is necessitated by HIV cure-related research at the EOL; (4) The sensitive nature of this research warrants robust oversight to ensure a favorable risk/benefit balance and to minimize the possibility of therapeutic misconception or undue influence; and (5) Research protocols should remain flexible to accommodate participants' comfort and needs at the EOL.
CONCLUSION
Because of the ethical issues presented by HIV cure-related research at the EOL, robust ethical safeguards are of utmost importance. The proposed ethical and practical considerations presented herein is a first step in determining the best way to maximize this research's impact and social value. More much inquiry will need to be directed towards understanding context-specific and cultural considerations for implementing EOL HIV cure research in diverse settings.
Identifiants
pubmed: 35012544
doi: 10.1186/s12910-022-00741-8
pii: 10.1186/s12910-022-00741-8
pmc: PMC8748179
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI164570
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI169609
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R21MH118120
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1033-1046
pubmed: 32449624
Clin Infect Dis. 2019 Aug 30;69(6):1063-1067
pubmed: 30715211
J Virus Erad. 2020 Apr 30;6(2):81-84
pubmed: 32405426
Palliat Med. 1994 Oct;8(4):298-305
pubmed: 7529102
AIDS. 2017 Jan 2;31(1):1-4
pubmed: 27755112
AACN Adv Crit Care. 2008 Apr-Jun;19(2):170-7
pubmed: 18560286
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
N Engl J Med. 2019 Nov 14;381(20):1889-1891
pubmed: 31722148
Nat Med. 2005 Nov;11(11):1145-9
pubmed: 16270065
PLoS One. 2020 Nov 18;15(11):e0242420
pubmed: 33206710
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
Histopathology. 2020 Aug;77(2):186-197
pubmed: 32443177
Am Fam Physician. 2005 Feb 1;71(3):515-22
pubmed: 15712625
Biogerontology. 2011 Dec;12(6):491-502
pubmed: 21604188
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1071-1082
pubmed: 32449625
Emerg Infect Dis. 2018 Mar;24(3):413-416
pubmed: 29460740
Ethics Behav. 2004;14(4):397-412
pubmed: 16625736
N Engl J Med. 2020 Feb 6;382(6):493-496
pubmed: 32023370
J Clin Oncol. 1992 Nov;10(11):1810-6
pubmed: 1403062
J Virus Erad. 2020 Aug 25;6(4):100008
pubmed: 33294210
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
J Clin Oncol. 2006 Jul 1;24(19):2987-90
pubmed: 16809725
Clin Infect Dis. 2019 Aug 30;69(6):1068-1070
pubmed: 30715193
BMC Med Ethics. 2018 Oct 20;19(1):83
pubmed: 30342507
J Empir Res Hum Res Ethics. 2018 Feb;13(1):3-17
pubmed: 28984168
Adv Anat Pathol. 2020 Nov;27(6):363-370
pubmed: 32732586
J Psychiatr Res. 2014 May;52:36-43
pubmed: 24507883
Palliat Med. 2016 Jun;30(6):533-48
pubmed: 26577927
ESC Heart Fail. 2020 Sep 22;:
pubmed: 32959998
Nat Biotechnol. 2016 Oct;34(10):1010-1014
pubmed: 27617737
Gerontologist. 2002 Oct;42 Spec No 3:86-98
pubmed: 12415138
Expert Rev Clin Pharmacol. 2019 Dec;12(12):1129-1143
pubmed: 31774001
JAMA. 2000 Nov 15;284(19):2476-82
pubmed: 11074777
J Pain Symptom Manage. 2000 Aug;20(2):130-9
pubmed: 10989251
Nurs Clin North Am. 2018 Mar;53(1):123-135
pubmed: 29362056
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e30-e36
pubmed: 29781880
PLoS One. 2021 May 7;16(5):e0250882
pubmed: 33961653